Bright Minds' shares soar on positive Phase 2 seizure reduction data

Bright Minds Biosciences said its selective serotonin receptor agonist succeeded in a mid-stage trial for two different types of seizures, and it plans to take the experimental drug into Phase 3 testing. The drug, called ...